TrialJournal for immunotherapy of cancer2026

Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study.

Guoxin Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.